A landmark study of gender medicine is caught in an ethics row

O that transgender medicine is such a fraught topic is that there is little evidence behind the arguments. When Hilary Cass, a British paediatrician, reviewed the field for an influential report published in 2024, she noted that most of the science underlying the prescription of puberty blockers and cross-sex hormones to teenagers (an approach called “gender-affirming care”) was “remarkably weak”.